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Abstract
Background: High risk oncologic Human Papilloma Virus (HPV) is one of the leading causes of cervical cancer
worldwide. We investigated HPV genotypes among women living or not with Human Immuno-deficiency Virus
(HIV) in two major hospitals in the south of the republic of BENIN in the city of Cotonou. Our objective is to
investigate the association of high risk-HPV to cervical dysplasia among women under stringent anti-retroviral (ARV)
treatment and in controls without HIV.
Methods: The investigation was carried out within 1 year period in two groups of adult women: one group with
HIV1 infection and under ARV therapy in the National University Hospital (CNHU-HKM) designated as CH group
(n = 86); and one control group without HIV infection and attending the hospital Mènontin for routine gynecologic
checkup and designated as ME group (n = 86). Cells derived from cervical uterine smears (CUS) were used for this
investigation. The samples in ME group were selected to have similar lamin A/C profile with CH group. HPV
genotypes were assessed by polymerase chain reaction (PCR) while lamin A/C expression profile was assessed by
western blotting to corroborate the risk of cervical dysplasia.
Results: HPV56 is dominant in CH group while HPV66 is dominant in ME group. 31 % of women in CH group are
infected with HPV compared to 23 % in ME group. Quadruple and quintuple HPV infections are more observed
among CH group but not in ME group making HPV counts of 43 in CH group and 27 in ME group. Cervical
dysplasia are present in 5 % (4/86) of women in CH group and in 1 % (1/86) of women in ME group at the time of
CUS collection. The adjustment of the risk to develop cervical cancer in the future related to HPV infection and the
total loss of lamin A/C is not significantly different in both groups.
Conclusion: Women living with HIV are more sensitive to multiple HPV infection but not all HPV infections
generated cervical dysplasia. The effectiveness of antiretroviral therapy in CH group may reduce significantly the
frequency of cervical dysplasia.
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Background
Human Papilloma Viruses (HPV) viruses come in di-
verse genotypes. High risk HPVs (HR-HPV) are some of
the leading causes of cervical cancer worldwide [1–6].
Over 200 genotypes have been identified and the HR-
HPVs are linked to the occurrence of cervical carcin-
omas [1–6]. Health disparities in developed and develop-
ing countries render some population such as African,
Asian, Hispanic and Mexican women more vulnerable
to these diseases [6]. The co-infection HPV/HIV is more
investigated due to the collaborative effects of both vi-
ruses to generate cervical dysplasia [7, 8]. HPV infec-
tions are more observed in population living with HIV
due to the deregulation of the immune system [9, 10].
Underneath the complex interaction between nuclear
components and viral components toward cancer devel-
opment, the stability of lamin A/C should always be
taken into consideration [11, 12]. Although the high fre-
quency of cervical dysplasia among women living with
HIV was often associated to the co-infection HPV/HIV
[1–8]; there are factors else than HPV that may also be
involved in cervical dysplasia [11, 12]. Studies performed
in four West African countries including Benin, has
shown that cervical cancer ranks number one in women
living with HIV and number second in women negative
for HIV [13]. The present study was done to verify the
HPV genotypes among women living with HIV and
treated with ARV compared to women with no HIV in-
fection and the association to the loss of lamin A/C and




The investigation was carried out within 1 year period in
two groups of adult women: one group with HIV1 infec-
tion and under ARV therapy in the National University
Hospital (CNHU-HKM), designated as CH group (n =
86); and one control group without HIV infection and
attending the hospital Mènontin for gynecologic routine
checkup and designated as ME group (n = 86). Women
in group CH with HIV1 infection are under stringent
anti-retroviral treatment at CNHU-HKM while women
in group ME without HIV infection are not receiving
any treatment. The CH group is under free stringent
ARV treatment program offered by the Ministry of
Health in BENIN.
The inclusion criteria are women of 20 to 60 years old
(average 38 years) and sexually active. The exclusion cri-
teria are women in menstruation or within third month
post-partum. Signed Informed consent was obtained
from all women before the collection of cervical uterine
smears (CUS). Sample collections were carried out in
the gynecological service under the supervision of a
gynecologist and nurses. The Cervical Uterine junction was
visualized with colposcopy before CUS collection [11, 12].
This study was approved by the Research Ethic Committee
of the Institute of Biomedical Science and Applications
(CER-ISBA), and by the Ministry of Health in Republic of
BENIN. HIV status was determined in the referral hospital
(CNHU-HKM) with a rapid HIV test (Determine(R), Abbott
Diagnostics) or Genie2(R) (Bio-Rad, Marnes-La-Coquette,
France) test as previously reported [13].
Cell collection and processing
To collect CUS for HPV and lamin A/C analyses, a dis-
posable sterile speculum was introduced in the vagina
along with a disposable cytobrush to reach the cervical-
uterine junction where cells were collected by rotating the
cytobrush clockwise twice. The brush was placed in a
50 ml collection tube containing 5 ml of sterile ice cold
phosphate buffer saline (PBS) to collect cells. Cells were
kept on ice and delivered within an hour to the laboratory
(Unit of Biochemistry and Molecular Biology UBBM,
Cotonou, BENIN) for processing. All collection tubes
were centrifuged to gather cell pellets which were washed
once with ice cold PBS before splitting them in several
Eppendorf tubes (i) for the extraction of genomic DNA to
genotype HR-HPV; (ii) for the analysis of lamin A/C pro-
teins by western blot. The procedures followed were in ac-
cordance with the ethical standards of our institutional
committee on human experimentation and in accordance
with the Helsinki Declaration as previously reported [12].
Reagents
HPV multiplex primers, Agarose powder, Ethylenedi-
aminetetraacetic acid (EDTA), 2- deoxyribonucleic
acid (DNA) ladder and ethidium bromide were from
Sigma-Aldrich (France). Tris-Base, glycine, sodium
dodecyl sulfate, bis-acrylamide and nitrocellulose
membrane, the protein ladder and the peroxidase
conjugated secondary antibodies anti-rabbit and anti-
mouse were purchased from Bio-Rad Inc (USA). So-
dium chloride (NaCl), potassium chloride (KCl),
Tween-20, protease inhibitor phenyl-methyl-sulfonyl
fluoride (PMSF), 2-mercaptoethanol, methanol, gly-
cerol, 1,4-Dithiothreitol (DTT), sodium fluoride
(NaF), sodium azide (NaN3), Tris-Hydrochloride (tris-
HCl) and sodium dodecyl sulfate (SDS, NaC12H25SO4)
were from Sigma-Aldrich (USA). The primary anti-
body against lamin A/C was purchased from Trans-
duction Lab (USA). Antibody against ß-tubulin was
from Santa Cruz Biotechnology (CA, USA). The
chemo-luminescence reagent “Super Signal West Dura
Extended Duration Substrate” made by PIERCE was
from Thermo Scientific (Rockford, IL USA) and was
used on Western blot membranes for protein revela-
tion after exposure to X-ray films [12].
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DNA extraction
DNA was extracted from cell pellets (i) by the phenol-
chloroform method after cell membrane disruption with
lysis buffer containing proteinase K (20 mg/ml) and
RNAse as previously reported [12]. Phenol was added to
the cell lysate (V/V) and centrifuged at 10,000 rpm at 4 °C
for 10 min to collect the upper aqueous phase into a new
Eppendorf tube followed by the addition of chloroform
(V/V) and another centrifugation (10,000 rpm at 4 °C for
10 min). The supernatant was collected in a new Eppen-
dorf tube and ice cold ethanol (96 %) was added at -20 °C
for 4 h to precipitate DNA. The DNA pellet was recovered
after centrifugation (12,000 rpm at 4 °C for 10 min), was
washed with ice cold ethanol (70 %) and then collected
after centrifugation at 12,000 rpm at 4 °C for 5 min. The
DNA pellet was air dried at 55 °C for 20 min, and solubi-
lized in tris-EDTA (TE) buffer. The concentration of DNA
was measured with a spectrophotometer (260 nm).
Soluble DNA extract is stored in freezer until needed
for genotyping of HPV by Polymerase chain reaction
“PCR” [12].
PCR and genotyping of HPV
The quality of DNA was assessed by amplifying ß-actin
gene before setting up the PCR with HPV multiplex
primers for genotyping. A nested multiplex PCR
(NMPCR) assay that combines degenerate E6/E7 con-
sensus primers and type specific primers was done as
previously reported [12]. For each PCR reaction, positive
and negative controls were used. A first consensus PCR
was performed with human sequences (GPEG from
SIGMA-Aldrich) to confirm the presence of HPV DNA.
After the first PCR the amplified product was used again
for a second amplification with the set of multiplex
primers (nested PCR) to determine the genotype of HPV
as previously described [12]. The multiplex primers used
can detect the high grade oncogenic HPV and the low
grade oncogenic HPV. The genotypes were divided in 4
groups according to the set of primers. The set 1 of
primers is able to detect HPV16; HPV 18; HPV 31; HPV
59; HPV 45 and yield PCR products of 457; 322; 263;
215 and 151 base pairs (bp), respectively. The set 2 of
primers is able to detect HPV 33; HPV 6/11; HPV 58;
HPV 52; HPV 56; and yield PCR products of 398; 333;
274; 229 and 181 bp respectively. The set 3 of primers is
able to detect HPV35; HPV 42; HPV 43; HPV 44 with
PCR products of 358; 277; 219 and163 bp respectively.
The set 4 of primers is able to detect HPV68; HPV 39;
HPV 51; HPV 66; yielding PCR products of 333; 280;
223 and 172 bp respectively. The PCR products were
run through 1.5 % agarose gel to separate amplicons ac-
cording to their size. Amplified bands were detected by
ethidium bromide staining under UV light. The HPV
genotype was determined according to the molecular
size of the band as specified previously [12].
Cell lysates and lamin A/C analysis
Cell pellets (ii) were put in lysis buffer A [50 mM tris-HCl
(pH 7.9), 150 mM NaCl, 0.1 mM EDTA, 1 % NP-40,
0.5 mM DTT, 0.5 mM PMSF, 30 mM NaF and 0.5 % pro-
tease inhibitor cocktail] and kept on ice for 30 min with
vigorous agitation every 5 min as previously described
[12]. Samples were boiled in SDS sample buffer for 5 min
and store in freezer until analysis. Before western blotting
protein samples were boiled again, loaded on 7.5 % SDS-
polyacrylamide gels and run at 100 volts for 2 h in tris-
glycine buffer, followed by a transfer to nitrocellulose
membranes with transfer buffer containing tris-glycine
and 20 % methanol. The membranes were blocked with
5 % milk in 1X Tris-buffered-saline (TBS) containing
0.1 % Tween-20 (TBST) for 30 min at room temperature
before incubation in primary antibody rabbit-anti-lamin
A/C at room temperature. The blots were washed 4 times
for 10 min with TBST and incubated with HRP-
conjugated secondary antibody anti-rabbit. The blots were
washed 4 times for 15 min with TBST and incubated for
3 min in Super Signal West Dura Extended Duration Sub-
strate before exposure to x-ray film and a film developer
for the detection lamin A/C or of ß-tubulin as a loading
control [12].
Statistical analyses
This study is a transversal case control study between HIV
infected group (CH) and non HIV group (ME). The Fisher
test (F-test) was used on Excel software to compare the
prevalence of HPV infection between groups CH and ME.
The CUS with HPV are given the value of 0 if there are
not infected with HR-HPV, the value of 1 if they are in-
fected with one type of oncogenic HPV, the value of 2 if
they are co-infected with two types of HR-HPV, the value
of 3 if they are co-infected with three types of HR-HPV,
the value of 4 when are co-infected with 4 types of HR-
HPV and the value of 5 when they are co-infected with
five types of HR- HPV; the difference between group CH
and ME is considered significant when p <0.05.
The non-parametric Mann-Whitney test was used to
compare lamin A/C profile between both groups. Lamin
A/C profiles were given the value of 3 when normal ex-
pression was observed, the value of 2 for weak expres-
sion of lamin A/C and the value of 0 for total absence of
lamin A/C. The difference between group CH and ME
groups is considered significant when p <0.05.
Video colposcopy
Women uterine cervix was examined with a video Colpos-
copy (SONY) by a gynecologist. Staining with dilute acetic
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acid followed by Lugol’s iodine solution was done to reveal
the cervical lesions if present. The lesions of the cervix ap-
peared white when stained with acetic acid (visual inspec-
tion with acetic acid, VIAA+) and yellow when stained
with Lugol’s iodine solution (visual inspection with Lugol’s
solution, VILI) as previously reported [11, 12].
Ethical considerations
The protocol of this study including objectives, partici-
pants, sample collection, analysis, and reporting of data
was approved by the Ethics Committee of the Institute
of Biomedical Sciences and Applications (CER-ISBA)
and by the Ministry of Health in Republic of BENIN.
The objectives of the study were explained to all partici-
pants before inclusion. Signed informed consent was
freely obtained from all participants before sample col-
lections for the study [12].
Results
HR-HPV status in HIV population (CH group)
Dual, quadruple and quintuple HR-HPV type co-
infections were observed in 7/86 (8 %) women in CH
group, {(HPV56, 58); (HPV58, 43); (HPV58, 42); (HPV
35, 42); (HPV 52, 42, 66, 39); (HPV 52, 43, 66, 39); (HP
V56, 33, 42, 39, 68)}. The HPV56 (9/86 = 10 %) is more
frequent than HPV58 (6/86 = 7 %) and HPV42 (6/86 =
7 %) followed by HPV 52 (4/86 = 5 %), HPV43(4/86 =
5 %) and HPV 39 (3/86 = 3 %), HPV 45 (2/86 = 2 %),
HPV 66 (2/86 = 2 %), HPV35 (1/86 = 1 %), HPV 33(1/86
= 1 %) and HPV 31(1/86 = 1 %) as shown in Fig. 1. Un-
predictably, HPV 18 and HPV16 were not detected in
CH group. Overall, the co-infection HR-HPV/HIV is
present in 31 % of women in CH group while HPV
counts including multiple HPV infections were 43.
HR-HPV status in non-HIV population (group ME)
Dual and triple HR-HPV co-infections were observed in
5/86 (5 %) of women in group ME: [HPV 45, 56];
[HPV43, 44]; [HPV18, 66]; [HPV42, 59, 68]; [HPV42, 59,
39]. In group ME, HPV 66 (4/86 = 5 %) is more frequent
than HPV58 (3/86 = 3 %), HPV56 (3/86 = 3 %), HPV33
(3/86 = 3 %) followed by HPV59 (2/86 = 2 %), HPV18 (2/
86 = 2 %) and HPV45 (1/86 = 1 %), HPV16 (1/86 = 1 %)
as shown in Fig. 2. Overall, HR-HPV infection was ob-
served in 23 % women of ME group while total HR-
HPV counts including multiple HR-HPV infections were
27. The diversity of HR-HPV genotypes makes hard to
use HPV as biomarker to follow women toward cancer
development in both groups.
Analysis of HR-HPV prevalence in HIV and non-HIV popu-
lations (group CH vs group ME)
More women in CH group have significantly higher HR-
HPV infections (27/86 = 31 %) than women in ME group
(20/86 = 23 %); p < 0.001, as shows in Fig. 3 and Table 1.
HR-HPV counts is higher in CH group with HIV infec-
tions (n = 43) compared to ME group without HIV (n =
27), p < 0.001. The length of ARV treatment in CH
group varies between 1 to 15 years (Table 1).
Cervical dysplasia in the context of HIV, HR-HPV and
lamin A/C deficiency
The prevalence of cervical dysplasia in both groups is












HPV66 HPV56 HPV58 HPV52 HPV45 HPV43 HPV42 HPV39 HPV35 HPV33 HPV31 HPV18 HPV16
HPV incidence in CH group
Fig. 1 Incidence of HPV types in HIV infected women in group CH. Genotype HPV56 is more frequent than HPV 58, HPV 42 followed by HPV52,
HPV43; HPV56, HPV39; HPV45, HPV66 and HPV35, HPV33, HPV31. HPV18 and HPV16 were not detected in this CH group
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infections and it is opportune in this instance to evaluate
the risk to develop cervical dysplasia with the deficiency
in lamin A/C. An example of western blot performed
with cell lysates derived from CUS samples in CH group
is shown in Fig. 4 with samples expressing lamin A/C
and without lamin A/C. Sample A1 expresses lamin A/C
while samples C1 and C2 have totally lost the expression
of lamin A/C. Samples C1 and C2 have more risk to de-
velop cervical cancer regardless of HIV and HR-HPV
status. Multiple HR-HPV co-infections were most ob-
served in women with low lamin A/C or no lamin A/C
along with cervical lesions (Figs. 5 and 6).
In CH group cervical dysplasia was observed in 4/86
(5 %) of women living with HIV. We observed low grade
cervical intraepithelial lesions (CIN-1) in one woman
(52 years old) with co-infections HIV/HPV58 and
HPV43; high grade lesions (CIN-2) in one woman











HPV66 HPV 59 HPV58 HPV56 HPV45 HPV42 HPV33 HPV18 HPV16
HPV incidence in ME group
Fig. 2 Incidence of HPV type in women without HIV infection in group ME. Genotype HPV 66 is more frequent than HPV58, HPV56, HPV33










CH puorg ME group
Percentage
23%
Fig. 3 Histogram representing the frequency of women infected with HPV in CH group with HIV and ME group without HIV. The percentage of
women with HPV infection in CH group (31 %) is significantly higher than in ME group without (23 %) with p < 0.001
Capo-chichi et al. Infectious Agents and Cancer  (2016) 11:43 Page 5 of 9
HPV 66 and HPV39; condylomatous epithelial lesions in
one woman (26 years old) with co-infections HIV/
HPV56, HPV33, HPV42, HPV39 and HPV68; condyl-
omatous epithelial lesions in one woman (28 years old)
with co-infections HIV/HPV HPV35 and HPV42. One
woman with co-infections HIV/HPV52, HPV42, HPV66
and HPV39 has not developed cervical lesions at the
time of CUS collection as shown in Fig. 5. The silencing
of lamin A/C is observed in 34 % of group CH and this
put them at risk to develop cervical dysplasia in the fu-
ture. All 4 women with cervical lesions in CH group
have lost the expression of lamin A/C at the time of
CUS collections associated with co-infection HIV/mul-
tiple HR-HPVs. Conversely not all HIV/multiple HR-
HPV co-infections developed cervical lesions at the time
of sample collection. The histogram integrating lamin
A/C, HR-HPV and cervical lesions data in CH group in-
fected with HIV is shown in Fig. 5 and verified that cer-
vical lesions are more associated to the deficiency of
lamin A/C than to HR-HPV infection.
In ME group without HIV infection, one woman with
HPV18 has developed cervical dysplasia (CIN I) at the
time of sample collection (1/86 or 1 %) associated to the
loss of lamin A/C. All other women with HPV infection
have not developed cervical lesions at the time of sample
collection but the silencing of lamin A/C is observed in
34 % of them and this put them at risk to develop cer-
vical dysplasia in the future (Fig. 6). Table 1 represents
the prevalence of HR-HPV infection among antiretro-
viral (ARV) treated women (CH group) and non HIV in-
fected control (ME group) and shows that HR-HPV
infection is not always associated with cervical lesions.
When considering the subgroup with lamin A/C defi-
ciency, the prevalence of HR-HPV infection in CH
group is 13 % while the prevalence of HR-HPV infection
in ME group is14% as shown in table; the difference was
not significant. In both groups the absence of lamin A/C
is a suitable prognostic factor for the risk to develop cer-
vical cancer in the future.
Two years follow-up of the women participating in this
study
Both groups are under the supervision of gynecologists
and are advised to perform CUS or colposcopy once a
year. We recalled all women investigated after our first
analysis in Mai 2014 for a 2 years follow-up in June
2016. Among the CH group, no new cases of cervical
dysplasia were reported; unexpectedly the woman with
co-infections HIV/HPV52, HPV42, HPV66 and HPV39
with no cervical lesions at the time of CUS collection
did not develop cervical lesions 2 years later but did
clear out all HPV genotypes as shown by gel photo in
Fig. 7 (CUS FCU-177) along with negative control (CUS
FCU-176). The 26 years old woman with quintuple HR-
HPV (HPV56, HPV33, HPV42, HPV39 and HPV68) and
condylomatous lesions is still receiving ARV treatment
and is in good health. All other women are still receiving
ARV treatment for free and are in good health. Among
the ME group, one woman with HPV and no lamin A/C
developed cervical lesions and two women with no HPV
but with total absence of lamin A/C developed cervical le-
sions and were treated by the gynecologist. Sample num-
bers are scrambled and could not be traced to the patients.
Discussion
HR-HPV genotypes fluctuate in each country and environ-
ment as well as the association of HIV/HR-HPV co-
Table 1 Summary of ARV treatment, lamin A/C, HPV and cervical lesions in CH and ME groups
CH group ME group
Lamin A/C (n = 86) Women with HPVs Cervical lesions Years with ARV (y) Lamin A/C Women with HPVs Cervical lesions Years with ARV
Normal N = 34 9 (10 %) 0 1–13 years Normal N = 35 5 (6 %) 0 No
Low N = 22 7 (8 %) 1 1–9 years Low N = 21 3 (3 %) 0 No
Absent N = 30 11 (13 %) 3 1–15 years absent N = 30 12 (14 %) 1 No
Total N = 86 31 % 5 1–15 years N = 86 23 % 1 No
Table representing the frequency of HPV infection in antiretroviral (ARV) treated women (CH group) and non HIV infected control (ME group). The HPV frequency
does not correlate with cervical lesions
Fig. 4 Silencing of Lamin A/C in cervical uterine smears (CUS). An
example of western blot showing lamin A/C in CUS samples of
women in CH group. Sample A1 expresses of lamin A/C while
samples C1 and C2 have lost the expression of lamin A/C
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infections to cervical dysplasia or cervical cancer [1, 3, 12].
Our study in the south of BENIN shows that HPV56 is
predominant among women leaving with HIV and is more
frequent than HPV 58 and HPV42 and HPV 66. Among
women in control ME group with no HIV infection, the
HPV 66 is predominant and is more frequent than
HPV58, HPV56.
In study done in Democratic Republic of the Congo
(Kinshasa) the most common HR-HPV types among














Fig. 5 Histogram integrating HPV, lamin A/C and cervical lesions data in CH group infected with HIV. In this CH group cervical lesions are more















Fig. 6 Histogram integrating HPV, lamin A/C and cervical lesions data in ME group without HIV infection. This ME group has less cervical lesions
associated to low or absence of lamin A/C
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HPV16. Among women with negative/unknown HIV
status, the most common HR-HPV types were HPV52,
HPV35 and HPV18 as reported [1]. In southwest China
(Yunnan) the most common HR-HPV types in women
infected with HIV were HPV52, HPV58, HPV18,
HPV16, and HPV33 as reported [4]. In Thailand the
most common HR-HPV types in the population were
HPV72, HPV52, HPV62, and HPV16 [3].
Although HR-HPV infections are more frequent in CH
group with HIV (Fig. 4), not all women infected with
HR-HPV will develop cervical dysplasia or cancer
(Figs. 5 and 6) and it is opportune to integrate other can-
cer biomarkers with HR-HPV analyses to efficiently pre-
dict the risk to develop cervical dysplasia independently to
viral infection. The discrepancy between the low rate of
cervical intra epithelial lesions and the high rate of HR-
HPV infections is striking in CH group and is an indicator
that the evaluation of HR-HPV genotypes solely is not suf-
ficient to define the risk to develop cervical lesions in
women living with HIV and under efficient ARV treat-
ment. The early detection of cervical lesions in women
with HIV allowed the gynecologist to apply cryotherapy
for these women.
Aside of viral integration into the genome, nuclear pro-
tein anomalies and chromosomal instabilities occur to ini-
tiate tumor formation and progression [14–17]. The
deficiency of lamin A/C was already demonstrated in sev-
eral studies to be a reliable prognostic factor for cervical,
ovarian, breast, prostate, gastro-intestinal, colon cancers
and neuroblastoma [11, 12, 14–21]. In BENIN, cervical
cancer ranked number one among women infected with
HIV but appreciative to the efficacy of ARV treatments re-
ceived in CH group the prevalence of cervical dysplasia is
not enormous as predicted by studies based on HR-HPV
infection rate [8, 13]. HPV did clear out from some
women without triggering cervical lesions as shown re-
ported by our 2-year follow-up periods.
Although the prevalence of HPV infection is signifi-
cantly higher in the CH group, the frequency of HR-
HPV infection adjusted to the deficiency of lamin A/C is
not significantly different in both groups investigated
making this assessment more predictable of the risk to
develop cervical cancer in the future. Due to the diver-
sity of virus types involved in cervical cancer develop-
ment and progression, we recommend to investigate
further more molecular biomarkers in living individual
for the screening and prevention of cervical cancer ra-
ther than taking solely into consideration HR-HPV in-
fection rate especially in African countries.
Conclusion
Women living with HIV are more sensitive to multiple
HR-HPV infections but not all HR-HPV infections gener-
ate cervical dysplasia. The effectiveness of antiretroviral
therapy in CH group may reduce significantly the fre-
quency of cervical dysplasia although it has no influence
on the prevalence of HR-HPV/HIV co-infection. Lamin
A/C should always be used as biomarker for cervical can-
cer screening associated to HR-HPV genotypes in African
countries to not skip women who develop cervical dyspla-
sia independently of HR-HPV infections.
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